• Halozyme Therapeutics Downgraded by SVB Leerink to Market Perform

    3 days ago - By ETF Daily News

    Halozyme Therapeutics was downgraded by equities researchers at SVB Leerink from an “outperform” rating to a “market perform” rating in a research note issued on Thursday, Marketbeat reports. They presently have a $42.00 target price on the biopharmaceutical company's stock. SVB Leerink's target price would indicate a potential upside of 26.96%...
    Read more ...